JAMA Network Home
Sign In
Original Investigation

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa

JAMA Dermatology 10.1001/jamadermatol.2026.2633

August 05, 2026 at 11:00 AM EDT

Read the full article

In this study, among currently approved monoclonal antibody therapies for HS, adalimumab showed dominant cost-efficiency performance across multiple health systems. These findings highlight substantial international variation in biologic drug pricing and provide a framework for value-based pricing in HS therapeutics.

Corresponding Author: John W. Frew, MBBS, PhD, The Skin Hospital, One Campbell St, Liverpool, NSW 2170, Australia (jfrew@skinhospital.edu.au).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2026.2633?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080526

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks